Filing Analysis
Aligos Therapeutics, Inc. reported its financial results for the period ending May 7, 2026. The filing serves as a routine disclosure of the company's results of operations and financial condition via a furnished press release.
Key Facts
- The report was filed on May 7, 2026, under Item 2.02 (Results of Operations and Financial Condition).
- A press release detailing the financial results was included as Exhibit 99.1.
- The filing was signed by Lesley Ann Calhoun, who serves as Executive Vice President, Chief Operating Officer, and Chief Financial Officer.
- The information in the filing is furnished and not deemed 'filed' for purposes of Section 18 of the Exchange Act.
Aligos Therapeutics entered into an exclusive license agreement with Xiamen Amoytop Biotech for the development and commercialization of pevifoscorvir sodium in Greater China. The deal provides Aligos with a $25 million upfront payment and eligibility for up to $420 million in future milestones plus royalties.
Red Flags
- The agreement is not yet effective and will terminate automatically if Amoytop shareholders do not approve the transaction within 45 days of execution.
- The license is restricted to a specific geographic territory (Greater China), leaving Aligos responsible for other major markets.
Key Facts
- Agreement signed on April 16, 2026, with Xiamen Amoytop Biotech Co., Ltd.
- Aligos receives a $25 million upfront cash payment.
- Potential development, regulatory, and commercial milestones total up to $420 million.
- Tiered, high single-digit royalties on net sales in mainland China, Taiwan, Hong Kong, and Macau.
- Amoytop assumes all costs for development, regulatory activities, and manufacturing within the licensed territory.
- The agreement is contingent upon Amoytop shareholder approval, expected within 30 days and required within 45 days.
Aligos Therapeutics announced that its Phase 2 B-SUPREME study for pevifoscorvir sodium will continue following a DSMB review, which recommended increasing the sample size for the HBeAg- cohort. Additionally, the FDA has granted Fast Track Designation to pevifoscorvir sodium for the treatment of chronic hepatitis B virus (HBV) infection.
Red Flags
- The requirement to increase sample size for 'statistical powering' may indicate that the observed effect size was lower than initially projected, potentially leading to increased R&D costs and extended trial timelines.
Key Facts
- The independent Data Safety Monitoring Review Board (DSMB) recommended the continuation of the Phase 2 B-SUPREME study.
- The DSMB recommended an increase in sample size for the Part 2a (HBeAg- cohort) to optimize statistical powering.
- Futility criteria for the HBeAg- cohort was not met during the first interim analysis.
- The FDA granted Fast Track Designation to pevifoscorvir sodium, a capsid assembly modulator (CAM-E).
- The drug is being investigated for the treatment of chronic HBV infection.
Aligos Therapeutics issued a press release on March 5, 2026, announcing its financial results and operations condition. The filing is a standard disclosure of periodic financial performance.
Key Facts
- Date of report: March 5, 2026
- Disclosed under Item 2.02: Results of Operations and Financial Condition
- Exhibit 99.1 contains the full press release
- Signed by Lesley Ann Calhoun, EVP, COO, and CFO